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Abstract
Hematopoietic cell transplantation (HCT) is a treatment for malignant and non-malignant 
disorders. However, sometimes the numbers of donor hematopoietic stem cells (HSC) are limiting, 
which can compromise the success of HCT. We recently published that collection and processing 
of mouse bone marrow (BM) and human cord blood cells in a hypoxic atmosphere of 3% O2 or in 
ambient air (~21% O2) in the presence of cyclosporine A yields increased numbers of HSC. We 
now show that collection and processing of mouse BM cells in ambient air in the presence of 
specific combinations of anti-oxidants and/or inhibitors of epigenetic enzymes can also enhance 
the collection of HSC, information of potential relevance for enhanced efficacy of HCT.
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Introduction
Hematopoietic stem cells (HSCs) reside in a hypoxic microenvironment in vivo (~1–5% 
O2). [1–6] However, upon contact with atmospheric levels of oxygen in ambient air (~21% 
O2), HSCs rapidly begin the process of differentiation to form hematopoietic progenitor 
cells (HPC). Most studies and hematopoietic cell transplantation (HCT) are carried out with 
cells collected in ambient air, but our previous work demonstrated that collection of cells in 
a hypoxia chamber (at 3% O2), not in ambient air, greatly increased HSC recovery from 
mouse bone marrow (BM) and human cord blood (CB). [7–8] We termed the phenomenon 
of ambient oxygen induced loss of HSCs as extraphysiologic oxygen shock/stress 
(EPHOSS). We could counteract the effects of EPHOSS generated when collecting mouse 
BM or human CB in ambient air if the collections in air were done in the immediate 
presence of cyclosporine A. However, use of cyclosporine A is not without technical 
problems, as the potency of cyclosporine A can vary from batch to batch and the exact 
amount of cyclosporine A used has to be carefully titrated, plus exposure of cells to 
cyclosporine A for too long can have toxic effect on the cells. [9]
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In order to delineate alternative means to collect mouse BM cells in ambient air but without 
loss of HSC, we assessed the collection of mouse BM cells in ambient air, but in the absence 
and presence of different compounds and their combinations to attempt to mimic the effects 
of ‘hypoxia harvest’ on HSCs. We found that combinations of either antioxidants or of 
epigenetic enzyme inhibitors, but not in the presence of only single agents, could enhance 
collection of mouse BM HSCs, and of additional interest, could further enhance the 
collection of HSCs after collection/processing in a 3% O2 hypoxic environment. These 
studies are of potential interest for clinical translation.
Methods
Mice
Female, 8–10 week old C57BL/6, Boy/J and C57BL/6J x Boy/J F1 (herein referred to as F1) 
mice were obtained from the on-site breeding core facility at Indiana University School of 
Medicine. All animal procedures were approved by the Indiana University Committee on 
Use and Care of Animals. Animals were maintained under temperature- and light-controlled 
conditions (21–24°C, 12 hour light/dark cycle) and were group-housed according to age and 
sex. Mice were fed ad libitum. Where indicated, BM was flushed from the femurs of 
C57BL/6 mice either at ambient air conditions or in a hypoxia chamber kept at 3% O2 as 
previously published. [7]
Inhibitors, antibodies and flow cytometry
All inhibitors used were from Selleck Chemicals (Houstin, TX). All inhibitors were used at 
the concentrations indicated. Inhibitors were present in all media starting at when the BM 
was flushed from the mouse femurs. All cells were in the presence of the inhibitor(s) for at 
least 1 hour prior to use in experiments. The inhibitors were not washed out. However, in the 
case of the transplantation experiments inhibitors were diluted out while creating the proper 
cell dose for transplantation. For flow cytometry, HSC were stained at room temperature for 
15 minutes with the following antibodies: Lineage cocktail (Lin)-FITC (BioLegend; cat. # 
133302), ckit-APC-H7 (BD Bioscience; clone # 2B8), Sca1-PE/Dazzle™594 (BioLegend; 
clone # D7), Flt3-APC (BioLegend; clone # A2F10) and CD150-BV421 (BD Bioscience; 
clone # Q38-480). HSC populations are defined as Lin−Sca1+ckit+ (LSK) CD150+ (see 
gating strategy provided in Figure 1A). CD3-APC-H7 (BD Bioscience; clone #145-2C11), 
B220-PE-CF594 (BD Bioscience; clone # RA3-6B2), CD11b-BV421 (BD Bioscience; clone 
#M1/70), CD45.1-FITC (BD Bioscience; clone # A20), CD45.2-APC (BD Bioscience; 
clone #104) were used for in vivo transplantation to assess donor BM cell engraftment. 
FACS analysis was performed with a modified BD Bioscience LSRII and FlowJo software 
(version 7.6.2; TreeStar, WA). The negative portion was determined by using relevant 
isotype antibody controls.
In vitro colony-forming unit (CFU) assay
Mouse BM cells were seeded in triplicate in 1.0 mL of methylcellulose culture medium (1% 
methylcellulose) supplement with 30% FBS, 2 mM L-glutamine, 0.1 mM 2-
mercaptoethanol, 0.1 mM hemin (Sigma-Aldrich), 5% vol/vol pokeweed mitogen mouse 
spleen cell conditioned medium and cytokines: 1 U/mL recombinant human erythropoietin 
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(Amgen; Thousand Oaks, CA), 50 ng/mL recombinant mouse SCF (R&D Systems). Plates 
were incubated at 5% CO2 and lowered 5% O2 in a humidified chamber. The number of 
colonies was scored at day 7 with an inverted microscope.[7,10]
In vivo transplantation
F1 mice (CD45.1+CD45.2+) were lethally irradiated (550cGy, two doses, 24 hours apart) 
and transplanted with 50,000 antioxidant or vehicle control treated C57BL/6 
(CD45.1−CD45.2+) BM cells and 100,000 Boy/J (CD45.1+CD45.2−) BM competitor cells 
within 24 hours after irradiation. [7,11] Peripheral blood (PB) was collected at various time 
points from host animals by submandibular vein bleeds. The blood samples were treated 
with red blood cell lysis buffer and then washed in PBS+0.5% BSA buffer before staining 
with CD45.1, CD45.2, CD3 (to determine T cells), B220 (to determine B cells) and CD11b 
(to determine myeloid cells) antibodies as described above. Mice were sacrificed 12 weeks 
after transplantation then BM cells were stained and analyzed by flow cytometry, but 
peripheral blood was assessed at 4 and 12 weeks.
Statistical analysis
Results are expressed as mean values ± standard deviation. P value less than 0.05 (two-tailed 
Student’s t-test) was considered as statistically significant.
Results and Discussion
Combination antioxidant treatment mimics ‘hypoxia harvest’
An environmental difference between ‘hypoxia harvest’ and ‘normoxia (ambient air 
collected) harvest’ is the oxygen level. We hypothesized that antioxidants, which inhibit the 
oxidation of molecules, may be able to prevent the effect of oxidative stress on HSCs 
induced by EPHOSS. Mouse BM cells were collected with 1 mM N-Acetyl-Cysteine 
(NAC), a classic antioxidant which has been proved be useful in many oxidative stress 
studies [12,13], in the flush media collected in ambient air. Cells were incubated with the 
inhibitor for 1 hour and remained in all media for the rest of the experiment. In our system, 
there was no significant change in numbers of collected HSC in ambient air in the presence 
of 1 mM NAC (Figure 1B–C). A higher dose of NAC (3 mM) was tested, with no increase in 
numbers of collected HSCs (data not shown). Then we added another antioxidant, ascorbic 
acid 2-phosphate (AAP) [14], to check whether this anti-oxidant, alone or in combination 
with NAC, could produce protection and increased numbers of HSCs collected in ambient 
air under the stress of EPHOSS. Co-treatment with 1 mM NAC and 0.22 mM AAP, but not 
AAP alone, significantly increased numbers of HSCs from 99 ± 6 per million BM cells to 
208 ± 17 per million BM cells (p<0.001), which is similar to the number of HSC collected 
in the hypoxia chamber without these added reagents: 235 ± 25 per million BM cells (Figure 
1A–C).
To check whether antioxidants treatment influenced HPC numbers, mouse BM cells treated 
with either antioxidants or vehicle control were seeded in methylcellulose medium and 
cultured for 7 days in the presence of cytokines. As shown in Figure 1D–F combination 
antioxidant treatment resulted in significantly decreased numbers of granulocyte/
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macrophage (CFU-GM), erythroid (BFU-E), and granulocyte/erythrocyte/macrophage/
megakaryocyte (CFU-GEMM) progenitors, demonstrating that combination antioxidant 
treatment produces the same decrease in progenitor cell numbers as does hypoxia collection 
and processing (Figure 1D–F).
Antioxidant treatment enhances HSC engraftment
To test the functional significance of antioxidant treatment on HSCs, lethally irradiated F1 
mice were transplanted with 50,000 C57BL/6 BM cells treated with antioxidant combination 
or vehicle control, and 100,000 competitive Boy/J BM cells. Significantly increased 
engraftment in PB at 1 and 3 months and BM at 3 months post donor cell infusion was 
observed in the combination antioxidant treated group, compared to the vehicle control 
group (Figure 2A–B), consistent with our previously published findings of enhanced 
engraftment when using hypoxia collected and processed mouse BM cells. [7] The increased 
chimerism of the anti-oxidant treated cells was apparent for B cells, T cells and myeloid 
cells (Figure 2C–E).
Epigenetic enzyme inhibitor treatment mimics and expands on hypoxia harvest
We also considered the possibility of chromatin remodeling and/or epigenetic change(s) 
during EPHOSS, and conducted a small-scale epigenetic inhibitor library screen to test 
whether selected epigenetic inhibitors could prevent the EPHOSS-induced HSC cell loss. 
Aurora A Inhibitor I (s1451) is an inhibitor of Aurora kinase. RG108 (s2821), is an inhibitor 
of DNA methyltransferase. Olaparib (s1060) is an inhibitor of PARP1/2. As shown in Figure 
3A, combinatory inhibitor treatment (with inhibitors in all medias from flush through 
experimental processing) for cell collection in ambient air with 10μM s1451 + 10μM s2821, 
or 10μM s1451 + 10μM s1060 significantly increased numbers of collected HSCs in air (2.1 
to 2.3 fold change; Figure 3A). As shown in Figure 3B–D, the combination of other 
inhibitors of Aurora kinase (s1103 and/or s1147; 10μM) with other inhibitors of DNA 
methyltransferase (s1200 and/or s1782; 10μM), or other inhibitors of PARP1/2 (s1004s 
and/or s2886; 10μM) also significantly increased HSC numbers. Thus, using combinations 
of anti-oxidants, or an inhibitor of Aurora kinase with either an inhibitor of DNA 
methyltransferase, or of PARP1/2 enhanced collections of mouse BM HSC in the presence 
of ambient air resulted in numbers that equated with those cells collected in hypoxia.
Of additional interest, combinatory inhibitor treatment for cells collected in the hypoxia 
chamber also showed dramatic increases of HSC compared to the numbers of HSCs 
collected in hypoxia without these reagents (Figure 3E). Thus, we have now identified a 
number of different means to further enhance collection of HSCs even during hypoxic 
collection of the BM cells.
Conclusions
Our previous study showed that brief exposure of mouse BM cells to air limits the efficiency 
of HSC recovery. [7,8] In this present study, based on the fact that the only difference 
between ‘normoxia harvest’ and ‘hypoxia harvest’ is the oxygen level, we tested several 
antioxidants and their combinations and found using in vitro and in vivo assays that one 
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antioxidant combination (NAC + AAP) could mimic ‘hypoxia harvest’. We also evaluated 
epigenetic enzymatic regulators by conducting a small-scale epigenetic enzyme inhibitor 
library screen, and found that some combinations of epigenetic enzyme inhibitors could also 
mitigate the apparent EPHOSS-induced HSC differentiation in air.
HCT, especially with CB, is limited to a degree by the numbers of HSCs found in single CB 
collections. [9,15,16] Means to enhance the collection of HSCs could have significant 
therapeutic effect. We have now identified with mouse BM cells alternative means to 
enhance the collection of HSC, information that may be of relevance to future efforts to 
enhance HCT. We consider this a start, not an end, to determining the most efficacious 
means to enhance the collection of HSC from different tissue sources. It is likely that other 
means may work to enhance collections of HSC. Whether these combinations of reagents 
will be useful for collection of human HSCs remains to be determined. Also, it may be 
possible to enhance the engraftment of these increased numbers of collected HSCs by 
increasing the homing capacities of these cells. [16–18]
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Abbreviations
HCT hematopoietic cell transplantation
HSC hematopoietic stem cell
BM bone marrow
HPC hematopoietic progenitor cell
CB cord blood
EPHOSS extraphysiologic oxygen shock/stress
F1 C57BL/6J x Boy/J
Lin lineage
LSK Lin−Sca1+ckit+
CFU colony-forming unit
PB peripheral blood
NAC N-Acetyl-Cysteine
AAP ascorbic acid 2-phosphate
CFU-GM granulocyte/macrophage progenitor
BFU-E erythroid progenitor
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CFU-GEMMgranulocyte/erythrocyte/macrophage/megakaryocyte progenitor
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Figure 1. Antioxidant treatment mimics hypoxia harvest
Bone marrow cells were harvested and processed in a hypoxic chamber. Groups exposed to 
air were removed from the chamber and placed in ambient air for 60 minutes. A: 
Representative contour plots of HSCs treated with antioxidant or vehicle. B: Numbers of 
HSC in 1 million mouse bone marrow cells (BMCs) treated by 1mM NAC and/or 0.22 mM 
AAP. C: Fold change of HSCs treat with NAC and AAP. D–F: Colony formation assay 
(CFU) shows treatment with NAC and AAP, similar to that of hypoxia collection/processing, 
prevents HSC differentiation, like hypoxia harvest. * p<0.05, ** p<0.01, *** p<0.001.
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Figure 2. Effect of antioxidant treatment on competitive mouse HSC engraftment
50000 antioxidant or vehicle control treated CD45.2+ C57BL/6 mouse bone marrow cells 
and 100000 CD45.1+ Boy/J competitive cells were infused into lethally irradiated dual 
CD45.2+/CD45.1+ F1 recipients. Data was collected 1 and 3 months after injection. A: 
Peripheral blood (PB) was collected at 1st month and 3rd month after transplantation and 
cells were stained for CD45.2 percentage. B: CD45.2 percentage in mouse bone marrow 3 
month after transplantation. C. CD45.2+ B cell, T cell and myeloid cell percentages in 
mouse bone marrow 3 month after transplantation. n=5 for mice each group. * p<0.05, ** 
p<0.01, *** p<0.001.
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Figure 3. Epigenetic enzyme inhibitor library screen identified compounds which mimic hypoxia 
harvest
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A: Fold change of HSCs after treatment with s1451 (Aurora kinase inhibitor), s2821 (DNA 
methyltransferase inhibitor) and s1060 (PARP1/2 inhibitor) (concentration: 10 μM) for 1 
hour. B: Fold change of HSCs after treatment with s1451 and another two DNA 
methyltransferase inhibitors, s1200 and s1782 (concentration: 10 μM). C: Fold change of 
HSCs after treatment with s1451 and another two PARP1/2 inhibitors, s1004 and s2886 
(concentration: 10 μM). D: Fold change of HSCs after treatment with s1060 (PARP1/2 
inhibitor) and another two Aurora kinase inhibitors, s1103 and s1147 (concentration: 10 
μM). E: Fold change of HSCs after treatment with antioxidants and inhibitors in air and 
hypoxia chamber. * p<0.05, ** p<0.01, *** p<0.001. n=3, 7 mice.
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